CD8A and pancreatic adenocarcinoma: Several studies [14,[64], [65], [66], [67]] found a sublethal RFH at 42 °C could significantly enhance the anti-cancer effects of LTX-315, LTX-401, and T-VEC on hepatic cancers or pancreatic adenocarcinoma through an increase in CD8+T cells, CD8+/IFN-γ+ T cells, CD8+/TNF-α+ T cells, and NK cells, along with a reduction in Tregs in the tumor microenvironment, thus achieving an optimal treatment effect.